| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/08/2004 | US20040067953 Combination therapy for treating, preventing or managing proliferative disorders and cancers |
| 04/08/2004 | US20040067905 Nucleic acid compositions for stimulating immune responses |
| 04/08/2004 | US20040067882 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 04/08/2004 | US20040067544 Invention shows that shear-induced mechanical force enhances strength of receptor-specific interactions between adhesion molecules such as FimH and target cells, and this phenomenon is dependent on structural properties of adhesion molecules |
| 04/08/2004 | US20040067524 Chlamydia protein, gene sequence and uses thereof |
| 04/08/2004 | US20040067517 Of given amino acid sequence; binds with antibodies to the causative agent; expressed by spirochetes of Borrelia burgdorferi |
| 04/08/2004 | US20040067515 Human proteinase molecules |
| 04/08/2004 | US20040067504 Novel zacrp8 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods of using them; useful in the study of collagen dimerization or oligomerization or in formation of fusion proteins |
| 04/08/2004 | US20040067490 Nucleic acid sequences, and antibodies that immunospecifically bind to the polypeptide, their derivatives, variants, mutants, or fragments of the novel polypeptide, polynucleotide, or antibody specific to the polypeptide |
| 04/08/2004 | US20040067484 A vaccine regimen for inducing immunity against Herpes Simplex virus that employs both a nucleic acid vaccine and a protein vaccine, with a selected adjuvant |
| 04/08/2004 | US20040067242 Multi-subtype FIV vaccines |
| 04/08/2004 | US20040067240 Therapeutic agent comprising a b-subunit of a protein toxin |
| 04/08/2004 | US20040067239 Genetically engineered P30 antigen, improved antigen cocktail, and uses thereof |
| 04/08/2004 | US20040067238 Novel compounds |
| 04/08/2004 | US20040067237 Using a rational selection of representative PspAs from various families of clades to produce broadly efficacious Pneumococcal vaccines |
| 04/08/2004 | US20040067236 In combination with a Th1-inducing adjuvant; vaccines |
| 04/08/2004 | US20040067235 Methods for the use of neurotoxin in the treatment of urologic disorders |
| 04/08/2004 | US20040067232 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays |
| 04/08/2004 | US20040067220 Blockade of T cell migration into epithelial GVHD target tissues as an approach to achieving anti-tumor effects against lymphohematopoietic malignancies without GVHD |
| 04/08/2004 | DE10239629A1 Nicht-rekombinate Subunit-Vakzine gegen Streptococcus suis-Infektionen des Schweines Non-recombinant subunit vaccines against Streptococcus suis infection in pigs |
| 04/08/2004 | CA2832136A1 Optimized fc variants and methods for their generation |
| 04/08/2004 | CA2816149A1 Optimized fc variants and methods for their generation |
| 04/08/2004 | CA2502735A1 Targeted cd1d molecules |
| 04/08/2004 | CA2500250A1 Humanized anti-granulocyte mn-3 antibody and uses thereof |
| 04/08/2004 | CA2500234A1 Hypoallergenic allergy vaccines based on the timothy grass pollen allergen phl p 7 |
| 04/08/2004 | CA2500189A1 Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-.beta. |
| 04/08/2004 | CA2499843A1 Novel compositions and methods for the treatment of psoriasis |
| 04/08/2004 | CA2499826A1 Cell separation compositions and methods |
| 04/08/2004 | CA2499816A1 Optimized fc variants and methods for their generation |
| 04/08/2004 | CA2499533A1 Use of excipients to increase dna uptake by swine muscle cells |
| 04/08/2004 | CA2499042A1 Functional mutations in respiratory syncytial virus |
| 04/08/2004 | CA2499038A1 Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| 04/08/2004 | CA2498787A1 Antibody for adcc and inducing cytokine production |
| 04/08/2004 | CA2498483A1 Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome |
| 04/08/2004 | CA2498383A1 Treatment of pathologies which escape the immune response, using optimised antibodies |
| 04/08/2004 | CA2494899A1 Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer |
| 04/07/2004 | EP1405862A2 Method for the identification of antigenic peptides |
| 04/07/2004 | EP1405643A1 Acellular pertussis vaccines and methods of preparation thereof |
| 04/07/2004 | EP1404876A2 Interferon alpha-14 polymorphism |
| 04/07/2004 | EP1404873A2 Chimeric immunomodulatory compounds and methods of using the same |
| 04/07/2004 | EP1404863A1 PIBs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE |
| 04/07/2004 | EP1404852A1 Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter |
| 04/07/2004 | EP1404841A2 Cyp1b1 nucleic acids and methods of use |
| 04/07/2004 | EP1404831A2 Type 2 cytokine receptor and nucleic acids encoding same |
| 04/07/2004 | EP1404819A2 Synthetic viruses and uses thereof |
| 04/07/2004 | EP1404816A2 Novel human hepatoma lines, methods for obtaining same and uses thereof |
| 04/07/2004 | EP1404813A2 Methods of culturing animal cells and polypeptide production in animal cells |
| 04/07/2004 | EP1404714A2 Nuclear hormone receptor ligand binding domain |
| 04/07/2004 | EP1404706A2 Mycobacterial antigens expressed during latency |
| 04/07/2004 | EP1404672A1 Tyrosine kinase inhibitors |
| 04/07/2004 | EP1404374A1 Slc2as as modifiers of the p53 pathway and methods of use |
| 04/07/2004 | EP1404368A2 Mutant forms of cholera holotoxin as an adjuvant |
| 04/07/2004 | EP1404367A2 Use of polyclonal anti-hiv goat serum as a therapeutic agent |
| 04/07/2004 | EP1404366A2 Combination therapy of gamma-interferon and b cell specific antibodies |
| 04/07/2004 | EP1404365A2 Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy |
| 04/07/2004 | EP1404363A2 Adjuvant composition for mucosal and injection delivered vaccines |
| 04/07/2004 | EP1404359A2 Methods of treatment involving human mda-7 |
| 04/07/2004 | EP1404355A1 Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| 04/07/2004 | EP1404350A2 Proteins associated with cell growth, differentiation, and death |
| 04/07/2004 | EP1404305A1 Pharmacological preparation made from a nanoparticulate mesomorphous polyelectrolyte lipid complex and at least one active ingredient |
| 04/07/2004 | EP1404298A2 A method for preparation of vesicles loaded with biological material and different uses thereof |
| 04/07/2004 | EP1404279A2 Mutant forms of cholera holotoxin as an adjuvant |
| 04/07/2004 | EP1404268A1 Treating epidermlyosis bullosa with thymosin beta 4 |
| 04/07/2004 | EP1226433B1 Method for identifying active anti-apoptosis compounds |
| 04/07/2004 | EP0889905B1 Cytokine antagonists and agonists |
| 04/07/2004 | EP0854914B1 Live vaccines against gram-negative pathogens, expressing heterologous o-antigens |
| 04/07/2004 | EP0726955B1 Chimeric proteins comprising borrelia polypeptides: uses therefor |
| 04/07/2004 | EP0712312B1 Suppression of inhibitors |
| 04/07/2004 | EP0596032B2 Induction of cytotoxic t-lymphocyte responses |
| 04/07/2004 | CN1487996A Transgenic transchromosomal rodents for making human antibodies |
| 04/07/2004 | CN1487951A Peptides having affinity for the GP 120 viral protein and use thereof |
| 04/07/2004 | CN1487840A Molecular antigen array |
| 04/07/2004 | CN1487839A Collectins as adjuvants |
| 04/07/2004 | CN1487838A Molecular antigen array |
| 04/07/2004 | CN1486990A Humanized gene engineering antibody resisting hepatitis E virus |
| 04/07/2004 | CN1144875C OMP 26 antigen of haemophilus influenzae |
| 04/06/2004 | US6716968 Apoptosis-related antigenic compounds of specified amino acid sequence; inhibition of cell apoptosis; antibodies for stimulation of cell apoptosis; immunoassay to determine rate of apoptosis in tissues |
| 04/06/2004 | US6716966 Therapeutic binding agents against MUC-1 antigen and methods for their use |
| 04/06/2004 | US6716823 Noninvasive genetic immunization, expression products therefrom, and uses thereof |
| 04/06/2004 | US6716821 Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| 04/06/2004 | US6716809 Antitumor |
| 04/06/2004 | US6716623 Compositions and methods for identifying antigens which elicit an immune response |
| 04/06/2004 | US6716603 Nucleic acids encoding a chloride channel protein |
| 04/06/2004 | US6716592 Materials and methods relating to the diagnosis and treatment of diabetes and obesity |
| 04/06/2004 | US6716591 B. burgdorferi polypeptides |
| 04/06/2004 | US6716590 Solubilization and recovery of plasmodial parasite protective antigenic factors from associated starting plasmodial parasite material |
| 04/06/2004 | US6716575 Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
| 04/06/2004 | US6716574 Osp-C derived peptide fragments |
| 04/06/2004 | US6716434 Composition and method for immunostimulation in non- mammalian vertebrates |
| 04/06/2004 | US6716433 Group a streptococcal vaccines |
| 04/06/2004 | US6716432 Altered and purified pneumolysin, substantially non-toxic and capable of eliciting protective immune response against pneumococcal bacteria in animal, comprising specified polypeptide with one to three amino acid substitutions |
| 04/06/2004 | US6716431 Rotavirus nonstructural protein 4 in which histidine or asparagine at amino acid position 47 is mutagenized to aspartic acid to produce alternative form which has reduced toxicity, while retaining its antigenicity and immunogenicity |
| 04/06/2004 | US6716430 Moderating immunology response |
| 04/06/2004 | US6716423 Diagnostic assays for detection of neospora infections in cattle; administering immunogen; breeding |
| 04/06/2004 | US6716422 Administering interleukin-12 and antigen-presenting cells pulsed with peptide to mammal to induce immune response; side effect reduction |
| 04/06/2004 | CA2147372C Multidrug resistance gene |
| 04/06/2004 | CA2087286C Thioether conjugates |
| 04/06/2004 | CA2042016C Recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnostic of tuberculosis |
| 04/06/2004 | CA2010321C Lymphocyte-associated cell surface protein |
| 04/01/2004 | WO2004027381A2 Methods and compositions related to inhibiting nuclear envelope breakdown |